Selected article for: "chronic GVHD host versus graft disease and host versus graft"

Author: Gavriilaki, Eleni; Sakellari, Ioanna; Anyfanti, Panagiota; Batsis, Ioannis; Vardi, Anna; Bousiou, Zoi; Lazaridis, Antonios; Nikolaidou, Barbara; Zarifis, Ippokratis; Masmanidou, Marianna; Yiannaki, Efthalia; Markala, Dimitra; Anagnostopoulos, Achilles; Douma, Stella; Gkaliagkousi, Eugenia
Title: Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation
  • Cord-id: syfheynz
  • Document date: 2020_12_21
  • ID: syfheynz
    Snippet: (1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (2) Methods: we enrolled consecutive adult alloHCT survivors without established cardiovascular disease and control individuals matched for traditional cardiovascular risk factors (January–December 2
    Document: (1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (2) Methods: we enrolled consecutive adult alloHCT survivors without established cardiovascular disease and control individuals matched for traditional cardiovascular risk factors (January–December 2019). Circulating microvesicles (MVs) of different cellular origins (platelet, erythrocyte, and endothelial) were measured by a standardized flow cytometry protocol as novel markers of vascular injury and pro-coagulant activity. (3) Results: we recruited 45 survivors after a median of 2.3 (range 1.1–13.2) years from alloHCT, and 45 controls. The majority of patients suffered from acute (44%) and/or chronic (66%) graft-versus-host disease (GVHD). Although the two groups were matched for traditional cardiovascular risk factors, alloHCT survivors showed significantly increased platelet and erythrocyte MVs compared to controls. Within alloHCT survivors, erythrocyte MVs were significantly increased in patients with a previous history of thrombotic microangiopathy. Interestingly, endothelial MVs were significantly increased only in alloHCT recipients of a myeloablative conditioning. Furthermore, MVs of different origins showed a positive association with each other. (4) Conclusions: endothelial dysfunction and increased thrombotic risk are evident in alloHCT recipients long after alloHCT, independently of traditional cardiovascular risk factors. An apparent synergism of these pathophysiological processes may be strongly involved in the subsequent establishment of cardiovascular disease.

    Search related documents:
    Co phrase search for related documents
    • active malignancy and acute myeloid leukemia: 1, 2
    • active malignancy and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active malignancy and liver renal: 1
    • acute coronary syndrome and liver renal: 1
    • acute endothelial syndrome and liver renal: 1
    • acute gvhd patient and lymphoblastic leukemia: 1
    • acute lymphoblastic leukemia and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute myeloid leukemia aml and liver renal: 1
    • acute myeloid leukemia aml and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute myeloid leukemia and liver renal: 1, 2
    • acute myeloid leukemia and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute syndrome and liver renal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute syndrome and liver renal function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute syndrome and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16